AI Engines For more Details: Perplexity Kagi Labs You
Blood Pressure Reduction: Bendroflumethiazide helps lower blood pressure by promoting the excretion of excess sodium and water through the kidneys, leading to decreased blood volume and reduced pressure within the blood vessels. By reducing blood pressure, bendroflumethiazide helps lower the risk of cardiovascular events such as heart attacks, strokes, and kidney damage associated with hypertension.
Edema Management: Thiazide diuretics like bendroflumethiazide are effective in reducing edema by increasing urine production and reducing fluid accumulation in the body. This can be beneficial for individuals with conditions such as congestive heart failure, liver cirrhosis, and kidney disorders, where fluid retention may occur.
Antihypertensive Effects: In addition to its diuretic effect, bendroflumethiazide may exert antihypertensive effects through other mechanisms, such as vasodilation and modulation of vascular tone. By promoting relaxation of the blood vessels, bendroflumethiazide helps improve blood flow and reduce peripheral resistance, contributing to its blood pressure-lowering effects.
Potassium and Electrolyte Balance: While bendroflumethiazide promotes the excretion of sodium and water, it also increases the excretion of potassium. Therefore, patients taking bendroflumethiazide may be at risk of developing hypokalemia (low potassium levels), which can lead to symptoms such as muscle weakness, fatigue, and cardiac arrhythmias. Monitoring of potassium levels and supplementation may be necessary in some cases.
Metabolic Effects: Thiazide diuretics like bendroflumethiazide can affect glucose and lipid metabolism. They may increase blood glucose levels and impair glucose tolerance, particularly in patients with diabetes or prediabetes. Additionally, thiazides may elevate serum lipid levels, including cholesterol and triglycerides, although the clinical significance of this effect remains debated.
Renal Function: Bendroflumethiazide may have renal protective effects in certain populations, particularly individuals with chronic kidney disease and proteinuria (excess protein in the urine). By reducing blood pressure and intraglomerular pressure, bendroflumethiazide helps slow the progression of kidney damage and preserve renal function over time.
Side Effects: Common side effects associated with bendroflumethiazide include dizziness, lightheadedness, headache, gastrointestinal upset, and electrolyte imbalances. Rare but serious adverse effects may include severe hypokalemia, hyponatremia (low sodium levels), hyperuricemia (elevated uric acid levels), and allergic reactions.
Interactions: Bendroflumethiazide may interact with other medications, including nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, lithium, and certain antidiabetic medications. These interactions can affect the efficacy and safety of bendroflumethiazide and may require dosage adjustments or monitoring.
Rank | Probiotic | Impact |
---|---|---|
genus | Bifidobacterium | Reduces |
species | Akkermansia muciniphila | Reduces |
species | Bacteroides uniformis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
species | Parabacteroides distasonis | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
0 | 1 | Akkermansiaceae | family | Decreases |
0 | 1 | Mediterraneibacter | genus | Decreases |
0 | 1 | Escherichia | genus | Decreases |
0 | 1 | Lacrimispora | genus | Decreases |
0 | 1 | Dorea | genus | Decreases |
0 | 1 | Shigella | genus | Decreases |
0 | 1 | Agathobacter | genus | Decreases |
0 | 1 | Phocaeicola | genus | Decreases |
0 | 1 | Bacteroides | genus | Decreases |
0 | 1 | Streptococcus | genus | Decreases |
0 | 1 | Parabacteroides | genus | Decreases |
0 | 1 | Thomasclavelia | genus | Decreases |
0 | 1 | Fusobacterium | genus | Decreases |
0 | 1 | Roseburia | genus | Decreases |
0 | 1 | Bifidobacterium | genus | Decreases |
0 | 1 | Clostridioides | genus | Decreases |
0 | 1 | Veillonella | genus | Decreases |
1 | 0 | Akkermansia | genus | Decreases |
0 | 1 | Odoribacter | genus | Decreases |
0 | 1 | Escherichia coli O1:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O139:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O141:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O145:H34 | no rank | Decreases |
0 | 1 | Escherichia coli O15:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O155:H21 | no rank | Decreases |
0 | 1 | Escherichia coli O158:H23 | no rank | Decreases |
0 | 1 | Escherichia coli O16:H48 | no rank | Decreases |
0 | 1 | Escherichia coli O170:H18 | no rank | Decreases |
0 | 1 | Escherichia coli O18ac:H14 | no rank | Decreases |
0 | 1 | Escherichia coli O19:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H5 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O20:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O25:H16 | no rank | Decreases |
0 | 1 | Escherichia coli O55:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O68:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O7:H15 | no rank | Decreases |
0 | 1 | Escherichia coli O78:H51 | no rank | Decreases |
0 | 1 | Escherichia coli O80:H26 | no rank | Decreases |
0 | 1 | Escherichia coli O84:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O85:H1 | no rank | Decreases |
0 | 1 | environmental samples | no rank | Decreases |
0 | 1 | unclassified Akkermansia | no rank | Decreases |
0 | 1 | Escherichia coli O103 | serogroup | Decreases |
0 | 1 | Escherichia coli O111 | serogroup | Decreases |
0 | 1 | Escherichia coli O119 | serogroup | Decreases |
0 | 1 | Escherichia coli O121 | serogroup | Decreases |
0 | 1 | Escherichia coli O145 | serogroup | Decreases |
0 | 1 | Escherichia coli O155 | serogroup | Decreases |
0 | 1 | Escherichia coli O157 | serogroup | Decreases |
0 | 1 | Escherichia coli O177 | serogroup | Decreases |
0 | 1 | Escherichia coli O26 | serogroup | Decreases |
0 | 1 | Escherichia coli O3 | serogroup | Decreases |
0 | 1 | Escherichia coli O43 | serogroup | Decreases |
0 | 1 | Escherichia coli O5 | serogroup | Decreases |
0 | 1 | Escherichia coli O78 | serogroup | Decreases |
0 | 1 | Escherichia coli O86 | serogroup | Decreases |
0 | 1 | Escherichia coli O91 | serogroup | Decreases |
0 | 1 | Escherichia coli H20 | serotype | Decreases |
0 | 1 | Escherichia coli O1:H42 | serotype | Decreases |
0 | 1 | Escherichia coli O1:HNT | serotype | Decreases |
0 | 1 | Escherichia coli O10:H32 | serotype | Decreases |
0 | 1 | Escherichia coli O10:K5(L):H4 | serotype | Decreases |
0 | 1 | Escherichia coli O100:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H- | serotype | Decreases |
0 | 1 | Escherichia coli O111:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O111:NM | serotype | Decreases |
0 | 1 | Escherichia coli O112ab:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O112ac:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O113:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O114:H49 | serotype | Decreases |
0 | 1 | Escherichia coli O118:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O123:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O125ac:K+:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O126:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H27 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O128:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O128ac:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O139:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O145:NM | serotype | Decreases |
0 | 1 | Escherichia coli O146:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O15:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O150:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O152:H23 | serotype | Decreases |
0 | 1 | Escherichia coli O153:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O156:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H- | serotype | Decreases |
0 | 1 | Escherichia coli O157:H43 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O157:NM | serotype | Decreases |
0 | 1 | Escherichia coli O16:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O165:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O167:H26 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O176:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O177:NM | serotype | Decreases |
0 | 1 | Escherichia coli O2:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O2:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O25:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O25:NM | serotype | Decreases |
0 | 1 | Escherichia coli O26:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O26:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O28ac:NM | serotype | Decreases |
0 | 1 | Escherichia coli O29:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O32:H37 | serotype | Decreases |
0 | 1 | Escherichia coli O39:NM | serotype | Decreases |
0 | 1 | Escherichia coli O44:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O45:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16:CFA/II | serotype | Decreases |
0 | 1 | Escherichia coli O6:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O69:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O7:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O7:K1 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O79:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O8:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O81:NM | serotype | Decreases |
0 | 1 | Escherichia coli O83:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O86:H34 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H9 | serotype | Decreases |
0 | 1 | Escherichia coli O9:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O91:H14 | serotype | Decreases |
0 | 1 | Escherichia coli O91:NM | serotype | Decreases |
0 | 1 | Escherichia coli O99:H6 | serotype | Decreases |
0 | 1 | Escherichia coli ONT:H33 | serotype | Decreases |
1 | 0 | Mediterraneibacter gnavus | species | Decreases |
1 | 0 | Escherichia coli | species | Decreases |
1 | 0 | Bacteroides fragilis | species | Decreases |
1 | 0 | Streptococcus parasanguinis | species | Decreases |
1 | 0 | Lacrimispora saccharolytica | species | Decreases |
1 | 0 | Dorea formicigenerans | species | Decreases |
1 | 0 | Agathobacter rectalis | species | Decreases |
1 | 0 | Phocaeicola vulgatus | species | Decreases |
0 | 1 | Shigella dysenteriae | species | Decreases |
0 | 1 | Shigella flexneri | species | Decreases |
0 | 1 | Escherichia albertii | species | Decreases |
1 | 0 | Parabacteroides distasonis | species | Decreases |
0 | 1 | Escherichia fergusonii | species | Decreases |
0 | 1 | Shigella boydii | species | Decreases |
1 | 0 | Bacteroides uniformis | species | Decreases |
1 | 0 | Thomasclavelia ramosa | species | Decreases |
0 | 1 | Streptococcus sp. HSISM1 | species | Decreases |
0 | 1 | Streptococcus sp. LPB0220 | species | Decreases |
1 | 0 | Parabacteroides merdae | species | Decreases |
0 | 1 | Shigella sonnei | species | Decreases |
0 | 1 | Escherichia marmotae | species | Decreases |
0 | 1 | Blautia parvula | species | Decreases |
0 | 1 | Escherichia sp. E4742 | species | Decreases |
1 | 0 | Fusobacterium nucleatum | species | Decreases |
1 | 0 | Roseburia hominis | species | Decreases |
1 | 0 | Bifidobacterium longum | species | Decreases |
1 | 0 | Clostridioides difficile | species | Decreases |
1 | 0 | Veillonella parvula | species | Decreases |
1 | 0 | Streptococcus salivarius | species | Decreases |
1 | 0 | Akkermansia muciniphila | species | Decreases |
1 | 0 | Odoribacter splanchnicus | species | Decreases |
1 | 0 | Bacteroides xylanisolvens | species | Decreases |
0 | 1 | Akkermansia glycaniphila | species | Decreases |
0 | 1 | Akkermansia massiliensis | species | Decreases |
0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. infantis | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. longum | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. suillum | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. suis | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 0 | 0 | |
ADHD | 0.6 | 0.6 | |
Age-Related Macular Degeneration and Glaucoma | 0.2 | 0.1 | 1 |
Allergic Rhinitis (Hay Fever) | 1.2 | 1 | 0.2 |
Allergies | 1.9 | 0.2 | 8.5 |
Allergy to milk products | 0.6 | 0.4 | 0.5 |
Alopecia (Hair Loss) | 0.4 | 0.4 | |
Alzheimer's disease | 1.5 | 1.6 | -0.07 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.1 | 0.5 | 1.2 |
Ankylosing spondylitis | 1.4 | 0.6 | 1.33 |
Anorexia Nervosa | 0.2 | 0.8 | -3 |
Antiphospholipid syndrome (APS) | 0.5 | 0.5 | |
Asthma | 1.5 | 0.4 | 2.75 |
Atherosclerosis | 1 | 0.1 | 9 |
Atrial fibrillation | 1.1 | 0.9 | 0.22 |
Autism | 2.3 | 2.7 | -0.17 |
Autoimmune Disease | 0.5 | 0.1 | 4 |
Barrett esophagus cancer | 0.1 | 0.1 | 0 |
benign prostatic hyperplasia | 0.4 | 0.1 | 3 |
Biofilm | 1.5 | 1.5 | |
Bipolar Disorder | 0.5 | 0.1 | 4 |
Brain Trauma | 0.1 | 0.2 | -1 |
Breast Cancer | 0.5 | 0.5 | |
Cancer (General) | 0.1 | 0.1 | 0 |
Carcinoma | 0.8 | 0.4 | 1 |
Celiac Disease | 1.4 | 0.5 | 1.8 |
Cerebral Palsy | 0.3 | 0.1 | 2 |
Chronic Fatigue Syndrome | 1.4 | 1.6 | -0.14 |
Chronic Kidney Disease | 1.3 | 0.3 | 3.33 |
Chronic Lyme | 0.1 | 0.1 | 0 |
Chronic Obstructive Pulmonary Disease (COPD) | 1 | 0.2 | 4 |
Chronic Urticaria (Hives) | 0.8 | 0.5 | 0.6 |
Coagulation / Micro clot triggering bacteria | 1 | 0.1 | 9 |
Cognitive Function | 0.5 | 0.2 | 1.5 |
Colorectal Cancer | 3 | 0.9 | 2.33 |
Constipation | 0.7 | 0 | 0 |
Coronary artery disease | 1.5 | 0.9 | 0.67 |
COVID-19 | 2.3 | 2.4 | -0.04 |
Crohn's Disease | 3.3 | 1.2 | 1.75 |
Cushing's Syndrome (hypercortisolism) | 0.4 | -0.4 | |
cystic fibrosis | 0.7 | 0.2 | 2.5 |
d-lactic acidosis (one form of brain fog) | 0.4 | 0.4 | |
deep vein thrombosis | 1.4 | 0.2 | 6 |
Denture Wearers Oral Shifts | 0.3 | 0.3 | |
Depression | 2.9 | 1.6 | 0.81 |
Dermatomyositis | 0.1 | 0 | 0 |
Eczema | 1 | 0.6 | 0.67 |
Endometriosis | 1.3 | 0.5 | 1.6 |
Eosinophilic Esophagitis | 0 | 0.1 | 0 |
Epilepsy | 1.5 | 0.4 | 2.75 |
erectile dysfunction | 0.5 | 0 | 0 |
Fibromyalgia | 0.6 | 0.3 | 1 |
Functional constipation / chronic idiopathic constipation | 1.9 | 0.7 | 1.71 |
gallstone disease (gsd) | 1.9 | 0.1 | 18 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.9 | 0.1 | 8 |
Generalized anxiety disorder | 1.6 | 0.3 | 4.33 |
Glioblastoma | 0.1 | -0.1 | |
Gout | 0.2 | 0.2 | 0 |
Graves' disease | 0.2 | 0.4 | -1 |
Gulf War Syndrome | 0.1 | 0.5 | -4 |
Halitosis | 0.4 | 0.1 | 3 |
Hashimoto's thyroiditis | 0.8 | 0.2 | 3 |
Heart Failure | 1.7 | 0.4 | 3.25 |
hemorrhagic stroke | 0.3 | 0.3 | |
Hidradenitis Suppurativa | 0.2 | 0 | 0 |
High Histamine/low DAO | 0.5 | 0 | 0 |
hypercholesterolemia (High Cholesterol) | 0.5 | 0 | 0 |
hyperglycemia | 0.9 | 0.3 | 2 |
Hyperlipidemia (High Blood Fats) | 0.1 | 0.1 | |
hypertension (High Blood Pressure | 1 | 0.9 | 0.11 |
Hypothyroidism | 0 | 0 | 0 |
Hypoxia | 0.4 | 0.4 | |
IgA nephropathy (IgAN) | 0.3 | 0.8 | -1.67 |
Inflammatory Bowel Disease | 3.1 | 2 | 0.55 |
Insomnia | 0.4 | 0.5 | -0.25 |
Intelligence | 0.7 | 0.7 | |
Intracranial aneurysms | 0.2 | 0.2 | |
Irritable Bowel Syndrome | 1.9 | 0.8 | 1.37 |
ischemic stroke | 0.8 | 0.6 | 0.33 |
Liver Cirrhosis | 2 | 1 | 1 |
Long COVID | 1.7 | 0.7 | 1.43 |
Low bone mineral density | 0 | 0 | |
Lung Cancer | 0.4 | 0.2 | 1 |
Lymphoma | 0.4 | 0.4 | |
Mast Cell Issues / mastitis | 0.5 | 0 | 0 |
ME/CFS with IBS | 0.1 | 0.4 | -3 |
ME/CFS without IBS | 0.6 | 0.8 | -0.33 |
membranous nephropathy | 0.1 | 0.1 | |
Menopause | 0.2 | 0.1 | 1 |
Metabolic Syndrome | 2.3 | 1.6 | 0.44 |
Mood Disorders | 2.1 | 1.4 | 0.5 |
multiple chemical sensitivity [MCS] | 0.2 | 0.2 | |
Multiple Sclerosis | 1.5 | 1.6 | -0.07 |
Multiple system atrophy (MSA) | 0.5 | 0 | 0 |
myasthenia gravis | 0.5 | 0 | 0 |
neuropathic pain | 0.4 | -0.4 | |
Neuropathy (all types) | 0.1 | 0.4 | -3 |
neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.4 | 0.6 | 1.33 |
NonCeliac Gluten Sensitivity | 0.2 | 0.1 | 1 |
Obesity | 2.4 | 1.7 | 0.41 |
obsessive-compulsive disorder | 1.9 | 1.1 | 0.73 |
Osteoarthritis | 1.2 | 0.2 | 5 |
Osteoporosis | 0.5 | 0.4 | 0.25 |
pancreatic cancer | 0.2 | 0.1 | 1 |
Parkinson's Disease | 1.8 | 2 | -0.11 |
Polycystic ovary syndrome | 2.3 | 0.3 | 6.67 |
Postural orthostatic tachycardia syndrome | 0 | 0 | |
Premenstrual dysphoric disorder | 0 | 0.1 | 0 |
primary biliary cholangitis | 0.3 | 0.3 | 0 |
Primary sclerosing cholangitis | 0.7 | 0.8 | -0.14 |
Psoriasis | 1.4 | 0.7 | 1 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.8 | 1.1 | 0.64 |
Rosacea | 0 | 0 | 0 |
Schizophrenia | 0.7 | 0.3 | 1.33 |
scoliosis | 0.4 | 0.4 | |
Sjögren syndrome | 0.6 | 0.7 | -0.17 |
Sleep Apnea | 0.4 | 0.1 | 3 |
Slow gastric motility / Gastroparesis | 0.6 | 0 | 0 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.7 | 0.1 | 6 |
Stress / posttraumatic stress disorder | 1.1 | 0.3 | 2.67 |
Systemic Lupus Erythematosus | 1.7 | 0.4 | 3.25 |
Tic Disorder | 0.4 | 0.2 | 1 |
Tourette syndrome | 0.3 | 0.1 | 2 |
Type 1 Diabetes | 1.3 | 0.6 | 1.17 |
Type 2 Diabetes | 2.9 | 1.9 | 0.53 |
Ulcerative colitis | 2.2 | 1.3 | 0.69 |
Unhealthy Ageing | 1.8 | 0.5 | 2.6 |
Vitiligo | 0.7 | 0.1 | 6 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]